Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lim

Showing results (1001-1010 of 1,029) with videos related to

Pageof 103
Sort By:
Nature Communications|June 15, 2026
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosisSofya Tishina, Alina Dahlhaus, Marta Manik, et al.
Annals of Clinical and Translational Neurology|February 8, 2023
Baseline characteristics of the North American prodromal Synucleinopathy cohortJonathan E Elliott, Miranda M Lim, Allison T Keil, et al.
Neurology|October 19, 2023
Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior DisorderJonathan E Elliott, Mohini D Bryant-Ekstrand, Allison T Keil, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2024
IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter StudyRonald Postuma, Nisa Vorasoot, Erik K St Louis, et al.
Nature Communications|May 14, 2024
mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolismTal Levy, Kai Voeltzke, Laura Hruby, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Neurology|January 5, 2024
Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy ConsortiumParichita Choudhury, Joyce K Lee-Iannotti, Andrea O Busicescu, et al.
Pageof 103

Showing results (1001-1010 of 1,029) with videos related to

Sort By:
Pageof 103
Nature Communications|June 15, 2026
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosisSofya Tishina, Alina Dahlhaus, Marta Manik, et al.
Annals of Clinical and Translational Neurology|February 8, 2023
Baseline characteristics of the North American prodromal Synucleinopathy cohortJonathan E Elliott, Miranda M Lim, Allison T Keil, et al.
Neurology|October 19, 2023
Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior DisorderJonathan E Elliott, Mohini D Bryant-Ekstrand, Allison T Keil, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2024
IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter StudyRonald Postuma, Nisa Vorasoot, Erik K St Louis, et al.
Nature Communications|May 14, 2024
mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolismTal Levy, Kai Voeltzke, Laura Hruby, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingDanny Rischin, Michael R Migden, Annette M Lim, et al.
The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Neurology|January 5, 2024
Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy ConsortiumParichita Choudhury, Joyce K Lee-Iannotti, Andrea O Busicescu, et al.
Pageof 103